HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J'adore

This article was originally published in The Rose Sheet

Executive Summary

Perfumed bath and shower gel, body creme, soap and deodorant debut Sept. 1 following the recent success of Christian Dior's J'adore fragrance. The scent represents 51% of the firm's fragrance business since its January launch, the LVMH division says (1"The Rose Sheet" May 22, In Brief). The ancillary products range in price from $18 for the 5 oz. soap to $60 for a 6.7 oz. body creme

You may also be interested in...



J'adore

Sales represent 51% of Christian Dior's fragrance business since J'adore's January launch, Dior reports. Available in 16 of the 26 accounts planned for the spring, J'adore sold $228,000 in its first two weeks on the market at Macy's West and became the best-selling fragrance at Burdine's, Parisians and Macy's East, the LVMH company announces

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel